Female genital tract secretions inhibit herpes simplex virus infection: Correlation with soluble mucosal immune mediators and impact of hormonal contraception

American Journal of Reproductive Immunology

Volumn 63, Issue 2, 2010, Pages 110-119

  Shust, Gail F ^a   Cho, Sylvia ^a   Kim, Mimi ^a   Madan, Rebecca P ^a   Guzman, Esmeralda M ^a   Pollack, Margaret ^a   Epstein, Julia ^b   Cohen, Hillel W ^a   Keller, Marla J ^a   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Genital herpes; Microbicides; Mucosal immunity; Reproductive hormones

Indexed keywords

HUMAN NEUTROPHIL PEPTIDE[1-3]; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 8; LACTOFERRIN; LYSOZYME; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLICULAR PHASE; HERPES SIMPLEX; HORMONAL CONTRACEPTION; HUMAN; HUMAN CELL; INNATE IMMUNITY; LUTEAL PHASE; MUCOSAL IMMUNITY; PRIORITY JOURNAL; VAGINAL LAVAGE;

ADOLESCENT; ADULT; CERVIX UTERI; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; GENITALIA, FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNITY, MUCOSAL; PILOT PROJECTS; PROSPECTIVE STUDIES; SOLUBILITY; VAGINA; YOUNG ADULT;

EID: 73949143582     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2009.00768.x     Document Type: Article

References (41)

1. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296:964-973.
2. Nagot N, Ouedraogo A, Konate I, Weiss HA, Foulongne V, Defer MC, Sanon A, Becquart P, Segondy M, Sawadogo A, Van de Perre P, Mayaud P. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis 2008, 198:241-249.
3. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids 2006, 20:73-83.
4. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992, 116:197-202.
5. Moss GB, Clemetson D, D'Costa L, Plummer FA, Ndinya-Achola JO, Reilly M, Holmes KK, Piot P, Maitha GM, Hillier SL. Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J Infect Dis 1991, 164:588-591.
6. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiegne-Traore V, Uaheowitchai C, Karim SS, Masse B, Perriens J, Laga M. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002, 360:971-977.
7. Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, Wallenstein S, Cole AL, Cole AM, Profy AT, Wira CR, Hogarty K, Herold BC. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. Aids 2007, 21:467-476.
8. John M, Keller MJ, Fam EH, Cheshenko N, Hogarty K, Kasowitz A, Wallenstein S, Carlucci MJ, Tuyama AC, Lu W, Klotman ME, Lehrer RI, Herold BC. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 2005, 192:1731-1740.
9. Mark KE, Wald A, Magaret AS, Selke S, Olin L, Huang ML, Corey L. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008, 198:1141-1149.
10. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM, Paavonen J, Morrow RA, Beutner KR, Stratchounsky LS, Mertz G, Keene ON, Watson HA, Tait D, Vargas-Cortes M. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004, 350:11-20.
11. Stamm WE, Handsfield HH, Rompalo AM, Ashley RL, Roberts PL, Corey L. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988, 260:1429-1433.
12. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277:1508-1510.
13. King AE, Fleming DC, Critchley HO, Kelly RW. Differential expression of the natural antimicrobials, beta-defensins 3 and 4, in human endometrium. J Reprod Immunol 2003, 59:1-16.
14. King AE, Critchley HO, Kelly RW. Innate immune defences in the human endometrium. Reprod Biol Endocrinol 2003, 1:116.
15. Herold BC, Siston A, Bremer J, Kirkpatrick R, Wilbanks G, Fugedi P, Peto C, Cooper M. Sulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens. Antimicrob Agents Chemother 1997, 41:2776-2780.
16. Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ, Lehrer RI, Herold BC. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 2006, 177:8658-8666.
17. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: part 2-Correlation between subjects. BMJ 1995, 310:633.
18. Usala SJ, Usala FO, Haciski R, Holt JA, Schumacher GF. IgG and IgA content of vaginal fluid during the menstrual cycle. J Reprod Med 1989, 34:292-294.
19. Schwartz JL, Mauck C, Lai JJ, Creinin MD, Brache V, Ballagh SA, Weiner DH, Hillier SL, Fichorova RN, Callahan M. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception 2006, 74:133-140.
20. Mauck CK, Ballagh SA, Creinin MD, Weiner DH, Doncel GF, Fichorova RN, Schwartz JL, Chandra N, Callahan MM. Six-day randomized safety trial of intravaginal lime juice. J Acquir Immune Defic Syndr 2008, 49:243-250.
21. Bollen LJ, Blanchard K, Kilmarx PH, Chaikummao S, Connolly C, Wasinrapee P, Srivirojana N, Achalapong J, Tappero JW, McNicholl JM. No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebo-controlled randomized clinical trial. J Acquir Immune Defic Syndr 2008, 47:253-257.
22. Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 2006, 193:27-35.
23. Fichorova RN. Guiding the vaginal microbicide trials with biomarkers of inflammation. J Acquir Immune Defic Syndr 2004, 37(Suppl. 3):S184-S193.
24. Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, Doncel GF. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 2004, 71:761-769.
25. Trifonova RT, Bajpai M, Pasicznyk JM, Chandra N, Doncel GF, Fichorova RN. Biomarkers of leukocyte traffic and activation in the vaginal mucosa. Biomarkers 2007, 12:608-622.
26. Smith JS, Herrero R, Munoz N, Eluf-Neto J, Ngelangel C, Bosch FX, Ashley RL. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. Sex Transm Dis 2001, 28:187-194.
27. Cherpes TL, Melan MA, Kant JA, Cosentino LA, Meyn LA, Hillier SL. Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis 2005, 40:1422-1428.
28. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004, 200:1337-1346.
29. Porter EM, van Dam E, Valore EV, Ganz T. Broad-spectrum antimicrobial activity of human intestinal defensin 5. Infect Immun 1997, 65:2396-2401.
30. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB, Ganz T. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest 1998, 101:1633-1642.
31. Cole AM. Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 2006, 306:199-230.
32. Hein M, Valore EV, Helmig RB, Uldbjerg N, Ganz T. Antimicrobial factors in the cervical mucus plug. Am J Obstet Gynecol 2002, 187:137-144.
33. Marchetti M, Trybala E, Superti F, Johansson M, Bergstrom T. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virol 2004, 318:405-413.
34. Marchetti M, Ammendolia MG, Superti F. Glycosaminoglycans are not indispensable for the anti-herpes simplex virus type 2 activity of lactoferrin. Biochimie 2009, 91:155-159.
35. Jenssen H, Sandvik K, Andersen JH, Hancock RE, Gutteberg TJ. Inhibition of HSV cell-to-cell spread by lactoferrin and lactoferricin. Antiviral Res 2008, 79:192-198.
36. Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, Barass C, Piconi S, Trabattoni D, Bwayo JJ, Plummer F, Clerici M, Broliden K. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr 2002, 30:413-420.
37. Belec L, Ghys PD, Hocini H, Nkengasong JN, Tranchot-Diallo J, Diallo MO, Ettiegne-Traore V, Maurice C, Becquart P, Matta M, Si-Mohamed A, Chomont N, Coulibaly IM, Wiktor SZ, Kazatchkine MD. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis 2001, 184:1412-1422.
38. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, Bwayo JJ, Nagelkerke N, Hasselrot K, Li B, Moses S, MacDonald KS, Broliden K. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. Aids 2008, 22:727-735.
39. Wilson CL, Schmidt AP, Pirila E, Valore EV, Ferri N, Sorsa T, Ganz T, Parks WC. Differential processing of {alpha}- and (beta}-defensin precursors by matrix metalloproteinase-7 (MMP-7). J Biol Chem 2009, 284:8301-8311.
40. Shaw JL, Petraki C, Watson C, Bocking A, Diamandis EP. Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense. Biol Chem 2008, 389:1513-1522.
41. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001, 16:469-475.